The U.S. Food and Drug Administration approved Bausch + Lomb’s ClearVisc dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery.

Oyster Point’s New Drug Application (NDA) for the dry eye disease therapy OC-01 was accepted for FDA regulatory review on the back of positive Phase III data.

Roche announced topline data from two identical Phase III trials (TENAYA and LUCERNE) of faricimab in neovascular or “wet” age-related macular degeneration (nAMD), with both studies hitting their primary endpoint.

REGENXBIO Inc. provided an update on the RGX-314 programs, including the announcement that the pivotal program for RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) is active.

On the heels of a significant new product introduction for a biotech client, full-service healthcare agency QBFox Healthcomm announced the promotion of three key staffers who drove the launch: Jason Doce, George Abdy and Mark Vespole. 

Roche

Swiss drugmaker Roche’s experimental eye medicine faricimab matched Bayer and Regeneron’s Eylea against diabetic macular degeneration in acuity gains in two studies, including one in which patients had less-frequent shots.

Three biopharma companies recently shuttered their clinical programs after either their drug compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints.

AbCellera and Kodiak Sciences announced a new partnership to create and develop therapeutic antibodies for ophthalmologic indications.

Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

The U.S. Food and Drug Administration approved Kala Pharmaceuticals’ Eysuvis for the short-term treatment of dry eye disease.